Navigation Links
Phase II trial of Bevacizumab (Avastin) in locally advanced cervical cancer 'promising'
Date:1/15/2014

An article published in the January issue of the International Journal of Radiation Oncology, Biology and Physics reports results of the Radiation Therapy Oncology Group (RTOG) phase II clinical trial of Bevacizumab (Avastin) in addition to cisplatin and pelvic radiation for locally advanced cervical cancer. The group reports that the addition of Bevacizumab to the existing standard of care was safe and showed promising overall results. The 2- and 3- year overall survival rates were 89.8 percent and 80.2 percent, respectively.

"Cervical cancer is a huge problem worldwide, but isn't as big a problem in the United States. So in many ways it tends to become a somewhat overlooked and under-studied disease," says Tracey Schefter, MD, investigator at the University of Colorado Cancer Center, director of the Stereotactic Body Radiation Therapy program at the University of Colorado School of Medicine, and the study's lead author.

Risk factors for cervical cancer include infection with the human papilloma virus (HPV). Screening dramatically reduces both the likelihood of developing cervical cancer and the disease's mortality rate. Combined, these two factors mean that 80 percent of the world's approximately 473,000 yearly cases of cervical cancer occur in the developing world. In the United States, cervical cancer rates have dropped 74 percent over the previous 50 years, but is still diagnosed in approximately 10,000 women per year, with 3,500 deaths due to the disease.

The current phase II clinical trial enrolled 49 eligible patients from 28 institutions in the years 2006-2009. The study previously reported that Bevacizumab was safe and well-tolerated in combination with cisplatin and radiation therapy in this population. Now the group reports on the secondary efficacy endpoints at a median follow-up time of 3.8 years.

Specifically the group evaluated the addition of 10mg/kg bevacizumab every two weeks for 3 cycles during
'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. ALS patients differ on treatment choices in later phases of disease
2. Reach2HD, a Phase II study in Huntingtons disease, launched
3. Analysis of KRYSTEXXA phase III data demonstrates improved health-related quality of life and physical function in refractory chronic gout patients
4. Phase III trial of dapivirine ring begins in Africa: New HIV prevention approach for women
5. IDRI and Medicago announce authorization to initiate a Phase 1 clinical trial for an H5N1 vaccine
6. COPD Foundation and BWH announces second phase of groundbreaking COPDGene project
7. JDRF announces winners of first phase of Agnes Varis Glucose-Responsive Insulin Challenge
8. Positive results from Phase 1/2 stem cell trial reported
9. New monoclonal antibody inhibits tumor growth in advanced solid tumors in phase I clinical trial
10. Teva to present new Phase III data for QNASL® Nasal Aerosol at the 2012 ACAAI Meeting
11. Edison Pharmaceuticals announces initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Phase II trial of Bevacizumab (Avastin) in locally advanced cervical cancer 'promising'
(Date:7/30/2014)... The Europe commercial aviation actuation system ... it is expected to reach $1,686.72 million by 2019 ... offers an exclusive range of opportunities and challenges which ... aviation has seen slumps in the past, yet the ... returned to its long-term growth rate of approximately 5 ...
(Date:7/30/2014)... 30, 2014 A marketing services ... technology startups is now available from Modern ... based in the Chicago region. The practice will ... information technology (IT), services, ecommerce, healthcare, private equity ... disciplines critical to startup success include competitive research, ...
(Date:7/30/2014)... Beach, CA (PRWEB) July 30, 2014 ... hired new employees and continues to grow quickly. Chris’ ... Suite 260, Laguna Beach, across the street from Three ... intersection. , Previous to State Farm, Chris had ... Restaurant industry headquartered in Irvine, California, where his responsibilities ...
(Date:7/30/2014)... Recently, Agebc.com, one of the most ... its new line of affordable flower girl dresses ... in several popular styles: sequined ball-gown, scoop neckline, fully ... company’s fresh assortment are: short chiffon dresses with delicate ... of course the classic beautiful colored tulle flower girl ...
(Date:7/30/2014)... teen who died of a caffeine overdose in May ... mass-consumed substance. To help prevent serious health problems that ... reporting progress toward a rapid, at-home test to detect ... and even breast milk. Their report appears in ACS, ... Mani Subramanian and colleagues note that caffeine,s popularity as ...
Breaking Medicine News(10 mins):Health News:Europe Aviation Actuation System Market is Expected to Reach $1,686.72 Million in 2019 - New Report by MicroMarket Monitor 2Health News:Europe Aviation Actuation System Market is Expected to Reach $1,686.72 Million in 2019 - New Report by MicroMarket Monitor 3Health News:Europe Aviation Actuation System Market is Expected to Reach $1,686.72 Million in 2019 - New Report by MicroMarket Monitor 4Health News:Startup Marketing Practice Launched by Modern Marketing Partners 2Health News:State Farm Agent Chris Risi Is Celebrating His Agency's 1st Year Anniversary In September 2Health News:Affordable Flower Girl Dresses Recently Unveiled at Agebc.com 2
... danger, study warns , MONDAY, June 1 (HealthDay News) ... eat enough to cover their energy output face the ... female athletes in the same circumstances, new research suggests. ... place dancers at higher risk for the "cardiovascular ...
... OTTAWA, June 1 /PRNewswire-FirstCall/ - MDS Nordion, a leading ... of,Canada and Atomic Energy of Canada Limited (AECL) to ... the MAPLE,project to address the current shortage of medical ... (NRU) reactor at Chalk River,Ontario - and to avoid ...
... EMERYVILLE, Calif., June 1 Bayer HealthCare Pharmaceuticals, Inc. ... today announced that the companies have begun enrolling patients ... (sorafenib) tablets in patients with non-squamous non-small cell lung ... treatments. , , "Nexavar has proven efficacy in ...
... Expands Veran,s electromagnetic (EM) navigation for oncology procedures. ... Veran Medical Technologies announced today that it has ... property. Veran secured a worldwide license to ... The Navigation division of Medtronic has developed ...
... twenty-somethings who attend or have graduated from private religious ... peers from public schools, according to sociological research published ... Health and Social Behavior . "This research suggests ... of social, financial and health-related factors that can make ...
... International (NYSE: VRX ) announced today that it ... SGP ) for taribavirin in Japan. In ... and release its last right of refusal on taribavirin under ... pursue partnering arrangements for the rest of the world. ...
Cached Medicine News:Health News:MDS Nordion Urges Government of Canada to Complete MAPLE Project to Address Current Medical Isotope Supply Shortage 2Health News:MDS Nordion Urges Government of Canada to Complete MAPLE Project to Address Current Medical Isotope Supply Shortage 3Health News:MDS Nordion Urges Government of Canada to Complete MAPLE Project to Address Current Medical Isotope Supply Shortage 4Health News:MDS Nordion Urges Government of Canada to Complete MAPLE Project to Address Current Medical Isotope Supply Shortage 5Health News:Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer 2Health News:Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer 3Health News:Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer 4Health News:Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer 5Health News:Veran Medical Technologies Announces Intellectual Property Agreement With Medtronic 2Health News:Religious devotion does not impact abortion decisions of young unwed women 2Health News:Valeant Grants Schering-Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal 2Health News:Valeant Grants Schering-Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal 3
(Date:7/30/2014)... , July 30, 2014 Stryker brand ambassadors ... week at the 3M Championship Champions Tour event near ... in Blaine . Stryker is the official joint ... Starting Friday, August 1 st through Sunday, August ... Mobility Zone; an on-site joint health destination located in the Pioneer ...
(Date:7/30/2014)... , July 30, 2014 Silicon Valley Bank, ... a study today that examines the merger, acquisition ... device companies.  According to the annual report based on ... potential returns since SVB started tracking the data in ... IPO.  Built on solid healthcare M&A activity over the ...
(Date:7/30/2014)... YORK , July 30, 2014 ACCESS ... for oncology supportive care, announced that its novel product ... in an article on OncLive.com titled, "Study Finds Mouth ... Cancers."  Dr. Steve Sonis , a leading expert ... seen in the oncology community for evidence-based strategies for ...
Breaking Medicine Technology:Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 2Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 3Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 4Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 5Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 3Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3
... the global leader in technology support and BPO services ... today the opening of its new Global Operations Center ... city of Dalian, will specialize in providing services in ... sponsors and clinical research organizations. With dramatic ...
... ARBOR, Mich., April 7, 2011 Adeona Pharmaceuticals, Inc. (AMEX: ... serious central nervous system diseases, announced today that it has ... its common stock at approximately $2.0725 per share to a ... million in gross proceeds. The investor will also receive warrants ...
Cached Medicine Technology:C3i Opens Asia Language Center in Dalian, China 2Adeona to Raise $3.5 Million in Registered Direct Offering 2Adeona to Raise $3.5 Million in Registered Direct Offering 3
... technology makes BURANE XL a ... array of aesthetic laser applications. ... controllable mode for coagulation, an ... procedures, and in particular a ...
... Test is an in vitro immunoassay intended for ... tumor associated antigen. It is indicated for use ... cancer in conjunction with cystoscopy or when prescribed ... by the FDA for prescription home use in ...
Used for measuring rectal pressure during urodynamic studies. All-silicone construction provides maximum softness and biocompatibility for enhanced patient comfort. Supplied sterile in peel-open pack...
Used for cystometry and urethral pressure profilometry. A loop is employed to enhance catheter retention and stabilization within the bladder. Supplied sterile in peel-open packages. Intended for one...
Medicine Products: